Hefei Lifeon Pharmaceutical Co Ltd

Lifang Pharmaceutical released its 2026 interim report. Total operating revenue was 684 million yuan, down 6.58% from the same period last year. Net profit attributable to the parent company was 88.2051 million yuan, down 2.24% year-on-year. Net cash inflow from operating activities was 162 million yuan. The asset-liability ratio was 24.28%, gross margin was 66.44%, return on equity was 4.79%, and diluted earnings per share was 0.39 yuan. The company had 15,200 shareholders, and the top ten shareholders held 64.10% of the total share capital.

On the morning of July 13, the innovative drug sector moved higher. Lifang Pharmaceutical hit its third consecutive daily limit up, Harbin Pharmaceutical Group rose for a second straight day, and Xintiandi, Yiling Pharmaceutical, Shuanglu Pharmaceutical, Haofan Bio, and Hisun Pharmaceutical all followed the uptrend. Earlier, Lifang Pharmaceutical announced that it had noticed some self-media outlets labeling it as a brain-computer interface concept stock, but the company has no brain-computer interface-related business or products. Its collaboration with Apon Medical is aimed at jointly exploring synergistic treatment options for attention deficit hyperactivity disorder and will not affect the company's performance. In addition, four of the company's products, including methylphenidate hydrochloride extended-release tablets, have been newly added to the National Essential Medicines List 2026 edition, but product sales remain uncertain. The company's first-quarter 2026 report showed total operating revenue of 357 million yuan, down 0.87 percent year on year, and net profit attributable to shareholders of 35.29 million yuan, down 7.74 percent year on year.